Erdafitinib, which targets the family of fibroblast growth factor (FGFR) tyrosine kinase receptors, is the first targeted therapy to be FDA-approved for the treatment of advanced urothelial carcinoma following platinum-based chemotherapy and harboring activating mutations or fusions in FGFR2 or FGFR3 [17]. This evidence concerns the gene FGFR3 and urothelial carcinoma.